Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

511 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vaccinomics and adversomics: key elements for a personalized vaccinology.
Laganà A, Visalli G, Di Pietro A, Facciolà A. Laganà A, et al. Among authors: di pietro a. Clin Exp Vaccine Res. 2024 Apr;13(2):105-120. doi: 10.7774/cevr.2024.13.2.105. Epub 2024 Apr 30. Clin Exp Vaccine Res. 2024. PMID: 38752004 Free PMC article. Review.
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.
Menzies AM, Long GV, Kohn A, Tawbi H, Weber J, Flaherty K, McArthur GA, Ascierto PA, Pfluger Y, Lewis K, Tsai KK, Hamid O, Prenen H, Fein L, Wang E, Guenzel C, Zhang F, Kleha JF, di Pietro A, Davies MA. Menzies AM, et al. Among authors: di pietro a. Neurooncol Adv. 2024 Mar 18;6(1):vdae033. doi: 10.1093/noajnl/vdae033. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38725995 Free PMC article.
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Yamazaki N, Queirolo P, Guenzel C, Polli A, Thakur M, di Pietro A, Ascierto PA. Schadendorf D, et al. Among authors: di pietro a. Eur J Cancer. 2024 Apr 24;204:114073. doi: 10.1016/j.ejca.2024.114073. Online ahead of print. Eur J Cancer. 2024. PMID: 38723373 Free article.
Impact of the COVID-19 pandemic on the infectious disease epidemiology.
Facciolà A, Laganà A, Genovese G, Romeo B, Sidoti S, D'Andrea G, Raco C, Visalli G, DI Pietro A. Facciolà A, et al. Among authors: di pietro a. J Prev Med Hyg. 2023 Nov 1;64(3):E274-E282. doi: 10.15167/2421-4248/jpmh2023.64.3.2904. eCollection 2023 Sep. J Prev Med Hyg. 2023. PMID: 38125993 Free PMC article.
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.
Climent MÁ, Álvarez C, Morales R, Maroto P, Rodríguez-Vida A, Méndez-Vidal MJ, Del Muro XG, Puente J, Láinez N, Vázquez S, Castellano D, Lang CG, Wang J, di Pietro A, Davis C, Sanz-Castillo B, Bolós MV, Valderrama BP. Climent MÁ, et al. Among authors: di pietro a. Clin Transl Oncol. 2023 Dec 15. doi: 10.1007/s12094-023-03358-4. Online ahead of print. Clin Transl Oncol. 2023. PMID: 38102374
511 results